LSZ102   Click here for help

GtoPdb Ligand ID: 12145

Synonyms: compound 10 [PMID: 29562737] | LSZ-102
PDB Ligand
Compound class: Synthetic organic
Comment: LSZ102 is a potent and orally bioavailable selective estrogen receptor degrader (SERD) [1]. It was developed for as a potential treatment for ERα positive breast cancer.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 95
Molecular weight 470.08
XLogP 6.61
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)/C=C/c1ccc(cc1)Oc1c(sc2c1ccc(c2)O)c1ccc(cc1C(F)(F)C)F
Isomeric SMILES FC(C)(F)c1c(ccc(c1)F)c1c(c2c(s1)cc(cc2)O)Oc1ccc(cc1)/C=C/C(=O)O
InChI InChI=1S/C25H17F3O4S/c1-25(27,28)20-12-15(26)5-9-18(20)24-23(19-10-6-16(29)13-21(19)33-24)32-17-7-2-14(3-8-17)4-11-22(30)31/h2-13,29H,1H3,(H,30,31)/b11-4+
InChI Key SJXNPGGVGZXKKI-NYYWCZLTSA-N
No information available.
Summary of Clinical Use Click here for help
LSZ102 was advanced to early stage clinical evaluation in a single study, but the trial was terminated.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02734615 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Phase 1 Interventional Novartis